Format

Send to

Choose Destination
See comment in PubMed Commons below
Atheroscler Suppl. 2013 Jan;14(1):175-8. doi: 10.1016/j.atherosclerosissup.2012.10.026.

Immunoadsorption in steroid-refractory multiple sclerosis.

Author information

  • 1Department of Nephrology and Rheumatology, Georg-August-University Goettingen, Robert-Koch-Str 40, D-37075 Goettingen, Germany. mkoziolek@med.uni-goettingen.de

Abstract

Multiple sclerosis (MS) is an autoimmune disorder, with involvement of both the humoral and cellular components of the immune system. The use of plasma exchange (PE) in steroid-refractory relapses has become an integral part of national and international guidelines for the treatment of steroid-resistant relapses of MS with an efficacy of 40-70%. So far, 6 studies of immunoadsorption (IA) treatment in different forms of MS have been published, 4 of them in steroid-refractory MS relapses. These 4 studies revealed a significant clinical improvement in 73-85% of patients with steroid-refractory MS relapses. However in MS patients with non-active relapsing-remitting or secondary progressive course, there was no clinical improvement. Despite the limited number of patients and studies, these data suggest a reasonably similar efficacy of IA in the treatment of steroid-refractory MS relapses compared to PE. More prospective trials are needed to confirm and extend these results.

Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk